You can see the complete list of today’s Zacks #1 Rank stocks here.ĪMN Healthcare has gained 24.4% against the industry’s 30.8% fall in the past year. AMN’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average beat being 15.6%. PDCO and McKesson Corporation MCK.ĪMN Healthcare, flaunting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 1.1%.
Some better-ranked stocks in the broader medical space are AMN Healthcare Services, Inc. The Zacks Consensus Estimate for the company’s third-quarter fiscal 2022 revenues is pegged at $25.5 million, suggesting a 6.7% improvement from the year-ago reported number. In the past 90 days, the Zacks Consensus Estimate for its earnings has widened from a loss of $1.10 to $1.15 per share. Surmodics is witnessing a negative estimate revision trend for 2022. The amount of revenues the company derives from such arrangements depends upon its ability or its licensees’ ability to successfully develop, obtain regulatory approval for, manufacture (if applicable), market and sell products incorporating Surmodics’ technologies. Reliance on Third Parties: A principal element of Surmodics’ business strategy is to enter into licensing arrangements with medical device and other companies that manufacture products incorporating its technologies. Despite Surmodics’ security measures, its information technology and infrastructure may be vulnerable to attacks by hackers resulting from employee error, malfeasance or other disruptions. The secure maintenance of this information is critical to its operations and business strategy, and the company’s customers expect that it will securely maintain their information. Downsidesĭata Security Threats: Surmodics collects and stores sensitive data, including intellectual property, its proprietary business information and that of its customers, suppliers and business partners, on its networks. Strong potential in the company’s Sublime Radial Access device and Pounce Arterial Thrombectomy platform raises our optimism about the stock. Surmodics confirmed making crucial progress on its SurVeil DCB pre-market approval submission. The company registered robust revenues from its IVD segment, as well as from its Product sales. Strong Q2 Results: Surmodics’ solid second-quarter fiscal 2022 results buoy optimism about the stock. Additionally, the data showed that no adjunctive thrombectomy devices were required to remove clots and 95% of these procedures could be performed while avoiding the use of thrombolytics within the target lesion. In April, Surmodics announced that its Pounce Thrombectomy System achieved 100% technical success in 20 FIH procedures. Thrombectomy Prospects Bright: Surmodics’ aim to leverage its proprietary Pounce thrombectomy platform technology to develop products raises our optimism.
launch of SurVeil will follow the receipt of the pre-market approval. The expectation continues to be that the U.S. During its fiscal 2022 second-quarter earnings call, Surmodics confirmed that it was anticipating that the 24-month TRANSCEND clinical data will be presented at an upcoming conference later this fall. SurVeil is a paclitaxel DCB used for the treatment of femoral-popliteal disease. Progress With TRANSCEND: Surmodics received investigational device exemption approval from the FDA for its SurVeil drug-coated balloon (“DCB”) pivotal study named TRANSCEND.
0 kommentar(er)
